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We analyzed the association between evolution of the 5V exon of tat and disease progression in an SIV/SHIV macaque model of opiate
dependence and AIDS. Cloned tat sequences were obtained by RT-PCR amplification of 3 plasma viruses (recovered at different times) from 6
morphine-dependent and 2 control Indian rhesus macaques inoculated with SHIVKU-1B SHIV89.6P and SIV/17E-Fr. Approximately ten clones
were sequenced for each animal per time point for use in phylogenetic analyses. We found a strong, significant inverse correlation between disease
progression and tat diversity in plasma by 20 weeks post-infection. The morphine-dependent macaques developed 2 distinct disease patterns –
rapid progressor (Group A) and slow progressor (Group B) – whereas control animals developed into slow progressor only (Group C). The three
animals in Group A exhibited ¨40% (P = 0.01) and ¨50% (P = 0.028) less diversity than Group B and C animals, respectively, over the 20
weeks. Furthermore, the Group A macaques showed a prominent reemergence of the wild-type SV17E tat sequence used in the inoculum that
coincided with disease progression. This suggests that the virus from the original infection represented the most pathogenic form among all
animals in these cohorts throughout the first 20 weeks of infection. We were unable to support or rule out a role for immune pressure on tat
evolution based on the spectrum of sequence changes in the data set. Thus, in the short duration of this study, the Tat-specific immune pressure
cannot explain the different disease outcomes of the six morphine animals nor of the two controls. Our results also suggest that in vivo morphine
dependence can contribute to the pathogenesis of SIV/SHIV infection and that it may do so in conjunction with the evolution of viral proteins,
such as Tat.
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Human immunodeficiency virus (HIV-1) infection ulti-
mately leads to development of acquired immunodeficiency
syndrome (AIDS). The interval between infection and onset of
clinical AIDS is influenced by range of factors. Injection drug
use (IDU) represents one such factor that may not only affect
intensity of the virus replication but it may also modulate
course of the disease progression (Nath et al., 2002). In United0042-6822/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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E-mail address: RJNoel@psm.edu (R.J. Noel).States alone, approximately 30% of the estimated new cases in
2003 were reported to be associated with IDU. However, the
relationship between IDU, mostly opiates, and HIV-1 progres-
sion remains unclear. Previously reported studies have indicat-
ed either a survival advantage or a diminished survival among
HIV-1-infected IDU (Alcabes and Friedland, 1995; Ronald
et al., 1994). In spite of this discrepancy, other reports have
unequivocally shown increased infection with bacteria and
other pathogens in experimental animals and also in HIV-
infected IDU population (Hilburger et al., 1997; MacFarlane
et al., 2000; Selwyn et al., 1992). The adverse effect of
substance of abuse has also been shown in an HIV-infected
cohort where cessation of drug abuse resulted in slower disease
progression (Ronald et al., 1994). Finally, opioids have been6) 127 – 138
www.e
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1990, 1991, 1992, 1993, 1994). Therefore, in spite of some
contradictory results, the majority of reports suggest that
opioids may adversely affect the HIV replication and onset of
clinical disease.
Like opioids, some viral proteins are capable of affecting
both viral replication and pathogenesis. The transactivator
protein (Tat), for example, is best known for its key role in viral
replication through stimulation of transcription elongation at
the viral promoter (Jeang and Berkhout, 1992; Kiernan et al.,
1999; Luo et al., 1993; Ruben et al., 1989) but also has
pleiotropic activities within the host and has been implicated
either directly or indirectly in a broad range of HIV-1-
associated pathologies (Jones et al., 1998; Kundu et al.,
1999; Raidel et al., 2002; Re et al., 1995). Tat is expressed
as a one-exon (72 amino acid) or two-exon (86–101aa) protein
depending on the stage of the viral life cycle (Karn, 1991;
Klotman et al., 1991; Munis et al., 1992; Rice et al., 1993; Rice
and Carlotti, 1990). Tat protein may be secreted from infected
cells, has paracrine activity (Verhoef et al., 1996; Zauli et al.,
2000; Chang et al., 1997; Ensoli et al., 1990; Magnuson et al.,
1995; Rautonen et al., 1994; Rusnati et al., 1997), and has been
detected in the CNS of HIV-1-infected persons (Hudson et al.,
2000). Anti-Tat antibodies (Re et al., 1995, 1996, 2001a,
2001b; Zagury et al., 1998; Demirhan et al., 1999) and well-
documented CTL responses (Addo et al., 2001, 2002; Allen
et al., 2000; Caputo et al., 2003; Dominici et al., 2003; Morris
et al., 2001) found in the blood of HIV-infected patients
provide additional evidence of the presence and potential
biological effects of extracellular Tat by crossing into non-HIV-
susceptible cells. Furthermore, as cessation of opioid use leads
to clinical improvement, interference with the biological effects
of Tat by anti-Tat antibody has been shown to decrease viral
replication and pathogenesis (Re et al., 1995; Zagury et al.,
1998). Tat alters expression of numerous host genes (Buona-
guro et al., 1992; Nath et al., 1999) and can produce oxidative
stress via down-regulation of antioxidant genes and up-regula-
tion of NO synthesis (Flores et al., 1993; Liu et al., 2002;
Nicolini et al., 2001; Polazzi et al., 1999; Torre et al., 2002;
Westendorp et al., 1995), including in astrocytes (Liu et al.,
2002). These non-LTR functions of Tat have been widely
implicated as a factor in HIV-1-associated illnesses such as
Kaposi’s sarcoma (Barillari et al., 1993; Ensoli et al., 1990;
Guo et al., 2004) and in HIV-associated dementia (HIVD)
(Anderson et al., 2002; Conant et al., 1998; Magnuson et al.,
1995; Mayne et al., 1998; Nath et al., 2000; Rappaport et al.,
1999) among other HIV-1-associated pathologies.
This overlapping spectrum of effects of Tat and opioids on
HIV-1 replication and progression raises the possibility that the
toxicity of Tat may be enhanced by the presence of morphine.
We have earlier shown that morphine dependence caused
higher virus replication in SIV/SHIV-infected Indian rhesus
macaques (Kumar et al., 2004). Furthermore, 50% of the
morphine-dependent animals showed accelerated development
of clinical disease, and they were euthanized within 20 weeks
of infection. The other half of the morphine-dependent and all
control animals developed slow disease, and they were stillalive 50 weeks after infection (unpublished observation). In
this communication, we examined the correlation between Tat
sequence diversity and disease progression in morphine-
dependent monkeys. Our results indicate an inverse correlation
between Tat diversity in plasma and disease progression.
Morphine-dependent rapid progressors showed lower Tat
evolution as compared to that in morphine-dependent slow
progressors and control macaques.
Results
We sequenced and analyzed a total of 233 clones of the
SIV tat exon 1 covering three time points post-infection with
SIV/SHIV from eight rhesus macaques in our primate model
of AIDS. Our emphasis was on the SIV/17E-Fr tat gene for
the following reasons. SIV/17E-Fr showed the widest tissue
distribution, including the cerebral compartment, and was the
first to cross the blood–brain barrier soon after infection
(results not shown). Tat is one of two viral proteins strongly
associated with neuropathology, and only the animals that
died during the course of this study showed severe
neurological effects of infection. Furthermore, since the two
SHIVs used in the inoculum had identical tat genes from
HIV-1, the source of any sequence diversity would have been
elusive. As a result of these factors, this analysis exclusively
examines the diversity of the SIV tat, rather than tat from
SHIV.
Of the eight monkeys, six formed a morphine-addicted
cohort. The animals in the morphine cohort segregated into
Group A, morphine + rapid progression, and Group B,
morphine + normal progression, according to their viral load
and CD4+ profiles (Table 1). Further justification for these
groups consisted of the rapid development of disease,
including severe neurological symptoms, requiring euthanasia
during the 20-week period of this study exclusively in the
animals of Group A. An additional two macaques were not
treated with opioids but otherwise were handled in a similar
manner to the morphine cohort with respect to viral infection.
These controls, Group C, show the most stable CD4+ and best
control of viremia, with an average of 286 CD4+ T cells/
Al blood (361 and 210 for 1/31P and 1/02P, respectively) as
well as the absence of neuroAIDS over the study period
(Table 1). Group A animals showed the most severe disease,
with an average of 22 CD4+ T cells/Al blood and the highest
viral loads that generally increased with time. Group B
animals, although they lack a treatment-related explanation
for their slower progression, showed a disease course
somewhere between the other groups, with an average
CD4+ level of 283 cells/Al blood and individual mean counts
of 46, 782, and 52 for 1/02N, 1/52N, and 1/56L, respectively.
With the single exception of 1/56L, the viremia of Group B
animals tended to decrease with time like Group C, indicating
that immune control was established over the infection in
these monkeys. Notably, 1/52N maintained exceptionally high
CD4+ counts and controlled the viral infection so well that we
were unable to amplify, clone, and sequence tat for the final
time point (week 20).
Table 1
CD4+ and total viral loads for Groups A, B, and C animals at weeks 4, 12, and
20
Monkey Sampling
timea (week)
CD4+ T
lymphocyte
(cells/ml)
Plasma
viral load
(105 copies/ml)
Group A 1/04L 4 45 1.20
12 16 40.1
18 2.9 684
1/28Q 4 36 2.03
12 21 203
20 6 766
1/42N 4 22 6.38
12 39 259
19 10 1980
Group B 1/02N 4 5 2.80
12 31 1.28
20 10 0.668
1/52N 4 274 1.36
12 707 0.0144
20 1365 0.00215
1/56L 4 112 3.12
12 31 4.06
20 13 1410
Group C 2/31P 4 536 8.32
12 334 0.314
20 214 0.176
2/02P 4 70 0.967
12 113 0.874
20 447 1.61
a No Group A monkeys survived beyond week 20. 1/04L was euthanized at
week 18, 1/28Q at week 20, and 1/42N at week 19.
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progression and death
EDTA plasma was collected at regular intervals from the
animals of both the morphine cohort (Groups A and B) and the
non-morphine cohort (Group C) after experimental inoculation
with SIV/SHIV. We collected tat exon 1 sequence data from
clones derived from bleedings at weeks 4, 12 and 20. Viral
RNA was extracted and amplified using a nested RT-PCR+
PCR reaction, prior to cloning and sequencing. In addition,
RNA was extracted from the viral stock of SIV/17E-Fr used in
the inoculum to assess any evolution of the virus during
maintenance in CEM cells. In fact, we found two changes in
the nucleotide sequence as compared to the GenBank record
for 17E. One change resulted in an altered codon at position 44
from tyrosine to serine, while the other change was functionally
silent. The sequenced clones represented a ¨500 base fragment
of SIV/17E-Fr encompassing the 1st exon of tat. Sequences
were truncated to the 300 base coding sequence for the first
exon, all of which represented native sequence as the primer
binding sites were located well outside of the tat coding
portion. The processed sequences were first compared phylo-
genetically within each animal, but without respect to time, to
assess overall divergence from the SIV/17E-Fr inoculum.
Phylogenetic tree analysis of the sequenced clones revealed
that the animals with fast disease progression exhibited the
lowest overall sequence diversity (Fig. 1). The three animals in
Group A had average distances of 0.32%, 0.30%, and 0.37%for 1/04L, 1/28Q, and 1/42N, respectively, for all time points
(Table 2). In addition, in the first panel of Fig. 1, the horizontal
branch lengths, which correlate with distance from SIV/17E-Fr
(root), are short, when accounting for the scale, compared to
the branch lengths of the monkeys in the lower two panels. The
remaining three morphine monkeys, Group B, showed disease
progression more similar to the controls and also indicated
greater diversity (Table 2 and Fig. 1). In fact, the average group
distances for Groups A and B, 0.33% versus 0.54%, are
significantly different (P = 0.01) as are the averages for Group
A and the Control group, 0.33% versus 0.63% (P = 0.028).
However, the difference in the mean distances of Groups B and
C was statistically indistinguishable.
Decreasing diversity and a return to the SIV17E form parallel
pathogenesis
Although the diversity is lowest among Group A monkeys
when all time points are considered together, an interesting
pattern is evident when the changes are examined over time.
The individual macaques in Group A, in general, have the
highest diversity at earlier (4 or 12 weeks) time points rather
than at 20 weeks (Fig. 2). For 1/28Q, there was a significant
drop in diversity from 0.67% to 0.07% (P < 0.001, all by
Wilcoxon signed rank test) from week 4 to week 20. In the
remaining Group A macaques, there is a significant drop from
week 12 to the final time point, 0.52% to 0.26% (P < 0.01) and
0.40% to 0.24% (P < 0.01), for 1/04L and 1/42N, respectively.
Group C animals clearly show the opposite pattern, with an
increase in diversity between 4 and 20 weeks—0.32% to
0.50% (P < 0.01) for 2/31P and 0.30% to 0.77% (P < 0.01) for
2/02P. As with CD4+ and viral load, the pattern for Group B
animals is intermediate. One animal, 1/56L, similar to 2/31P
and 2/02P, shows a clear increase in diversity over time,
moving from 0.37% to 1.01% diversity (P < 0.001). However,
animal 1/02N showed a pattern somewhat similar to 1/04L with
a rise in diversity between week 4 and 12 (P > 0.05) followed
by an overall drop from week 4 to week 20, 0.53% to 0.37%,
P < 0.05. The last animal in Group B, 1/52N, had such
effective control of viral replication that no data are available at
week 20 to indicate the level of viral diversity present over the
full time of this study.
The amino acid changes in Tat do not explain the varied
disease progression among the groups
Based on the inferred amino acid sequences, derived by
computer translation of the cloned genomic sequence frag-
ments, there is no obvious pattern of amino acid substitution to
explain the different disease outcomes in Groups A and B
monkeys nor in the control group. Fig. 3 presents a summary of
all amino acid substitutions for each group compared to the
starting SIV inoculum, with the clones identical to the starting
virus excluded. As expected based on the phylogenetic
distances calculated for the nucleotide sequences (Figs. 1 and
2, Table 2), the bar graph (Fig. 3B) shows that Group A
animals have the greatest fraction of clones identical to SIV/
Fig. 1. Phylogenetic trees of divergent Tat exon 1 sequences. All DNA sequences were collected and edited using BioEdit to truncate sequences to the tat exon 1
coding region. Sequences were aligned using ClustalX, and all sequences identical to the inoculum virus (17E) were removed for simplification. Trees were
generated from the aligned files using ClustalX and viewed using 17E as the root. The distance scale is indicated in the lower left of each tree.
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finally Group C with the lowest overall similarity to the starting
viral inoculum. All three groups showed a similarly wide
distribution of changes over the 99 amino acids of the first
exon. No group appears to have a remarkably greater density of
changes at the amino acid level. Even within the essential
cysteine-rich and basic domains (marked in Fig. 3A), the total
number of changes in these regions does not vary appreciably,
with five in Group A, seven in Group B, and four in Group C.
The total number of nonsense mutations (result in premature
truncation of the first exon) is also not greatly different—two in
Group A, five in B, and one in C. The timing of these
mutations, however, tends to be later in Groups B and C,
falling predominantly in week 20 rather than in weeks 4 and 12
as in Group A. This pattern supports the rate of change at thenucleotide level in Fig. 2. One prominent pattern does emerge
in 2/02P. There is a unique serine to proline change (S Y P) at
position 28 in 70% of week 12 2/02P clones. The same change
persists in 50% of week 20 sequences yet is not found in any
other monkey, raising the possibility of immune pressure. It is
also noteworthy that there is no other single change that is
present in any animal at greater than 30% frequency that does
not result in a premature stop.
The nature and frequency of nucleotide changes do not support
immune selective pressure at the 5V exon of tat by week 20
post-infection
Despite the suggestion of a role of the immune system
driving the S Y P change in 2/02P, there was no evidence for
Table 2
Average nucleotide distances of plasma-derived tat exon 1 clones from SIV17E-infected macaques
Monkey Total
sequences
Mean
distance (%)
Standard
deviation (%)
Group mean
distance (%)
t test
Group A morphine + fast progression 1/04L 32 0.32 0.32 0.33 A Y B
P = 0.0101/28Q 30 0.30 0.33
1/42N 28 0.37 0.29
Group B morphine + normal progression 1/02N 28 0.57 0.66 0.54 B Y C
P = 0.2241/52N 17a 0.44 0.38
1/56L 27 0.61 0.53
Group C control + normal progression 2/31P 41 0.48 0.44 0.63 A Y C
P = 0.0282/02P 29 0.78 0.53
a 1/52N has clones available only for the 4- and 12-week time points.
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synonymous and nonsynonymous changes as well as their ratio
(dS/dN) to indicate the potential for selective pressure. The
mean values of synonymous substitutions (functionally silent)
and substitutions that resulted in a changed amino acid
(nonsynonymous) were determined for all pairwise compar-
isons between 4 and 12 weeks or 4 and 20 weeks (Table 3).
Statistical significance was determined using the Wilcoxon
signed rank test as done previously (Lorenzo et al., 2004).
Although there were statistically valid differences in the mean
substitution patterns, the ratio of silent to altered site mutations
never dropped below 1. This does not disprove immune
selective pressure, but it neither provides support for the
development of a specific immune response to the 5V exon of
tat within the time frame studied.
Discussion
We find that, while control (Group C) animals exhibit
normal progression with controlled viral replication and
maintenance of acceptable CD4+ counts without exception,
the morphine-dependent animals showed variable disease
progression quite early during infection. This variance fell into
two distinct patterns. Group A animals showed rapid disease
progression, severe CD4+ loss, uncontrolled viremia, develop-
ment of severe neurological complications (including aggres-
sive behavior, motor disturbances, tremor, and ataxia), and
indeed all succumbed to disease by week 20 (results not
shown). Meanwhile, Group B monkeys, which were experi-
mentally indistinguishable from their Group A counterparts,
showed a disease presentation much more like Group C—with
intermediate viremic control, moderate CD4+ recovery, and
survival past the timeframe of this study.
Although the experimental manipulation of Groups A and
B animals was identical and, unlike the group C cohort, does
not explain the variable phenotype, examination of the viral
evolution at the first exon of tat has provided a possible
correlation. Tat sequences in Group B show a statistically
significant increased diversity when compared to the Group
A monkeys. This same pattern exists when Group C and
Group A monkeys are compared. On the other hand, no
apparent or statistical difference exists in the Tat exon 1
diversity over 20 weeks between Group B and Group C
animals.Within this overall diversity difference, an interesting
pattern does emerge to lead us toward a possible mechanism.
Group A monkeys did exhibit the lowest overall sequence
diversity for tat exon 1 when all time points were considered,
yet they also showed the earliest peak in diversity of Tat, which
then dropped over time as the original SIV/17E-Fr inoculum
virus reemerged as the dominant form during end-stage
disease. In general, the kinetics of Tat diversification showed
a negative slope over time for Group A animals but showed a
positive relationship (increased diversity with increased time)
in both Groups B and C. In effect, the molecular picture of
CD4+, viral load, and tat diversity and survival of the three
morphine monkeys in Group B was either intermediate to
leaning far toward the molecular profile of the control cohort.
This difference in tat evolution offers a possible explanation
for the variable clinical outcome within the cohort of
morphine-addicted monkeys.
Although we found no support at the nucleotide sequence
level for the emergence of Tat-specific immune pressure
(dS/dN >> 1 for all monkeys at all time points), these same
analyses are not capable of ruling out this possibility. An
interesting observation in a single animal, 2/02P, did show a
pattern of change that has been reported before. The region
containing the sequence STPESANL has been previously
reported to represent a CTL epitope (Allen et al., 2000). In
particular, Allen et al. found that changes in this epitope
appeared almost exclusively in Mamu-A*01-positive maca-
ques and resulted in CTL escape in vitro. Although we cannot
directly propose that mechanism being applicable in our
animals because of lack of information regarding MHC typing,
it remains a distinctly possible explanation for persistence of
the S Y P change from week 12 to week 20 in this monkey.
The amino acid changes, which unlike silent nucleotide
substitutions have the potential to be functionally involved in
the clinical distinctions within these groups, are scattered
throughout the 99 amino acids of the first exon of Tat. No
apparent pattern emerges, either in density or consistency of
changes, from the summary of all the divergent Tat proteins
encoded by the sequences acquired in each group. Again,
however, a pattern does emerge when we examine the
relationship between changes and time. As with the nucleotide
changes, the changes in amino acids accumulate over time in
Groups B and C, while they diminish and return to the original
SIV inoculum over time in Group A. However, a major caveat
Fig. 2. Mean diversity over time for individual macaques. For each animal, the sequences for one time point (4, 12, or 20 weeks) were aligned, and a distance matrix
was calculated using BioEdit. The mean of these distances for each time is plotted versus time, where mean percent diversity indicates the average number of
changes per 100 nucleotides for all clones in each macaque at any one time post-infection. (A) Group A time versus diversity for morphine + fast progressors. (B)
Group B time versus diversity for morphine + normal progressors. Sequences for 52N 20 weeks were unavailable. (C) Group C time versus diversity for Control
animals. The means of all time points for each animal are summarized in Table 2.
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to develop adequate diversity required for the selection of
immune variant of the parent virus. It is possible that other
more diverse loci, such as env, may show the evidence of suchpressure only within Groups B and C animals. Furthermore, the
reemergence of the Fwild-type_ SIV sequence as a major form
in all of the monkeys that died by week 20 (Group A) is
potentially influenced by the fact that SIV/17E-Fr is a highly
Fig. 3. Inferred amino acid tat exon 1 sequences. (A) The tat exon 1 coding sequences were translated to amino acids using BioEdit. Only sequences with nucleotide
changes causing an amino acid substitution (nonsynonymous change) are included in each group. The parent inoculum sequence is 17E and serves as the reference
within each group. Each sequence is represented by animal week-clone in the left column, and all changes from 17E are indicated in the right column. The cysteine-
rich and basic domains are indicated by solid and dashed lines, respectively. Positions of identity are indicated by a dot (.) and stop codons by an asterisk (*). (B) The
bar graph represents the percentage of the total number of sequenced clones for each animal in each group that did not vary from the 17E amino acid sequence.
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Table 3
Mean synonymous and nonsynonymous nucleotide substitutions at 4, 12, and 20 weeks
Monkey Sample time (week) Mean dS T SD P value
a Mean dN T SD P value
a Mean dS/dN T SD P value
a
Group A 1/04L 4 0.006 T 0.009 0.000 T 0 na
12 0.009 T 0.011 P < 0.5b 0.001 T 0.003 2.697 T 0.999
18 0.004 T 0.008 0.0003 T 0.002 3.613 T 0.015
1/28Q 4 0.018 T 0.010 0.002 T 0.004 4.014 T 1.893
12 0.022 T 0.004 P < 0.05b 0.002 T 0.004 4.005 T 1.540
20 0.022 T 0.004 P < 0.05c 0.002 T 0.004 3.708 T 1.369 P < 0.05c
1/42N 4 0.003 T 0.003 0.005 T 0.002 3.500 T 0.872
12 0.007 T 0.005 0.003 T 0.002 3.230 T 1.015
19 0.008 T 0.006 0.001 T 0.001 3.870 T 0
Group B 1/02N 4 0.021 T 0.003 0.004 T 0.006 3.000 T 0.868
12 0.02 T 0.002 0.006 T 0.008 P < 0.01b 2.763 T 1.089 P < 0.001b
20 0.022 T 0.004 0.003 T 0.004 3.666 T 1.481 P < 0.001c
1/52N 4 0.004 T 0.008 0.003 T 0.005 3.500 T 0.872
12 0.002 T 0.000 P < 0.001b 0.003 T 0.004 3.399 T 0.866
1/56L 4 0.015 T 0.015 0.001 T 0.001 4.843 T 2.119
12 0.023 T 0.004 P < 0.05b 0.003 T 0.002 4.537 T 1.645
20 0.025 T 0.008 P < 0.01c 0.009 T 0.007 2.559 T 1.892
Group C 2/31P 4 0.013 T 0.011 0.000 T 0.002 4.114 T 1.298
12 0.009 T 0.013 P < 0.001b 0.002 T 0.004 P < 0.001b 3.468 T 1.228 P < 0.01b
20 0.008 T 0.010 P < 0.001c 0.004 T 0.006 P < 0.001c 3.052 T 1.649 P < 0.001c
2/02P 4 0.013 T 0.011 0.001 T 0.001 3.630 T 0.000
12 0.029 T 0.010 P < 0.001b 0.004 T 0.005 P < 0.001b 5.087 T 2.691
20 0.031 T 0.012 P < 0.001c 0.004 T 0.005 P < 0.001c 5.227 T 3.193 P < 0.01c
The frequencies of synonymous (dS) and nonsynonymous (dN) substitutions were estimated by using the Synonymous/Nonsynonymous Analysis Program (SNAP)
from the Los Alamos HIV Sequence Database (http://hiv-web.lanl.gov/content/hiv-db/SNAP/WEBSNAP/SNAP.html). SD indicates standard deviation.
a P values were calculated using the Wilcoxon signed rank test. Non-significant differences are excluded for simplification.
b The significance values represent all pairwise comparisons between the 4- and 12-week time points.
c The significance values represent all pairwise comparisons between the 4- and 20-week time points.
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potential impact of SHIV Tat on this system and recognize
that this could be a confounding factor that we cannot address
with this data.
It is possible that the difference in evolution of Tat in this
study is dependent on the level of pathogenicity of the inoculum
virus. We were not surprised to discover that morphine abuse
became a demonstrable risk for disease progression in our study.
However, we expected that the evolution of Tat would correlate
directly, rather than inversely, with disease progression in our
animals. In hindsight, our model system may have, in some
manner, predisposed our results. These findings and the
associated caveats that arise from the study design do raise an
interesting issue. SIV/17E-Fr is a well-characterized neuro-
pathogenic variant (Zink et al., 2001; Zink and Clements, 2002;
Zink et al., 1998). Only Group A animals developed neuroAIDS
and died in the course of this study. Furthermore, we know that
SIV/17E-Fr was the first and predominant virus to enter the
CNS, thus suggesting a lesser role of the SHIVs at least in the
rapid progressors. Tat is well documented as a potential major
player in the development of neuroAIDS (Eugenin et al., 2005;
Banks et al., 2005; Andras et al., 2005). Finally, morphine has
also been shown to enhance HIV Tat-mediated neurotoxicity
(Gurwell et al., 2001; Khurdayan et al., 2004). This is the first
report suggesting a potential relationship between Tat diversity,
morphine addiction, and clinical progression to AIDS. How-
ever, the evolution of Tat in the cerebral compartment of these
animal may provide better understating for accelerated disease
in morphine-dependent macaques.Materials and methods
Animal model
The eight male rhesus macaques (Macaca mulatta) used
ranged in age from 1.5 to 2.5 years and weighed 3 to 4.2 kg at
the start of this study. The animals were negative for simian T-
cell leukemia virus type 1 and simian retrovirus. These
macaques were housed in the Animal Resource Center of the
University of Puerto Rico, San Juan. The experimental protocol
was approved by the Institutional Animal Care and Use
Committee, and the research was performed in accordance
with the Guide for the Care and Use of Laboratory Animals.
The macaques were divided into two groups, with one group
used for establishment of morphine dependence and the other
group used as a control. The morphine dependence was
established by injecting increasing doses of morphine (1 to 5
mg/kg of body weight over a 2-week period) by the
intramuscular route at 8-h intervals. These animals were
maintained at three daily doses of morphine (5 mg/kg) for an
additional 18 weeks. The control animals were given the same
amount of normal saline at the same time. All macaques were
infected by the intravenous route with a 2-ml inoculum
containing 104 50% tissue culture infective doses each of
simian–human immunodeficiency virus SHIVKU-1B (Singh et
al., 2002), SHIV89.6P (Reimann et al., 1996a, 1996b), and SIV/
17E-Fr (Flaherty et al., 1997). This combination of challenge
virus results in induction of uniform disease leading to clinical
AIDS in a relatively short time (Kumar et al., 2002), rather than
R.J. Noel Jr., A. Kumar / Virology 346 (2006) 127–138 135variably over multiple years when a single virus is used
(Kumar et al., 2001; Silverstein et al., 2000). These animals
were monitored for a period of 20 weeks. Blood was collected
into EDTA vacutainer tubes for this study at weeks 4, 12, and
20. The animals were maintained on morphine throughout the
observation period and monitored for CD4 profile and viral
load in the plasma.
CD4+ counts and viral load
Circulating CD4+ T-cell levels were determined by staining
for CD3, CD4, and CD8 surface markers. Approximately 105
peripheral blood mononuclear cells (PBMC) were stained with
10 Al of a mixture of antibodies against CD3, CD4, and CD8.
The unbound antibodies were removed by washing the cells
with cold phosphate-buffered saline (PBS). The cells were
fixed with 0.5% paraformaldehyde and analyzed with a
FACScalibur. The viral loads in plasma were determined in
duplicate by using a real-time reverse transcription-PCR (RT-
PCR) assay (Amara et al., 2001). The RNA copy number was
determined by comparison with an external standard curve
consisting of in vitro transcripts representing bases 211 to 2101
of the SIVmac239 genome. This assay has a sensitivity of 80
copies/ml of plasma.
Amplification, cloning, and sequencing of 5V exon of tat
Viral RNA was isolated from plasma samples at the weeks
indicated using the QIAmp Viral RNA Mini Kit (Qiagen, Inc.,
Valencia, CA) according to the manufacturer’s protocol. Viral
RNA at the SIV tat exon 1 locus was amplified by RT-PCR and
then secondary PCR. The RT-PCR reaction was performed
using the Qiagen One-Step RT-PCR kit using primers SvTat1F1
(5V-GGCAGGGGGATGGAGACCAGG) and SvTat1R1 (5V-
GCACAAAAAAGGGGAATTGTCGC). The secondary PCR
reaction was performed using Taq DNA polymerase (Promega,
Madison, WI) and primers SvTat1F2 (5V-AAATGAAGGAC-
CACAAAGGGAACC) and SvTat1R2 (5V-CCCATAGACACT-
TAAAAGCAAGATGGC). The 491 base pair fragment was
confirmed by agarose electrophoresis prior to cloning into
pCR2.1 using the TOPO TA Cloning Kit (Invitrogen, Carlsbad,
CA). Positive clones were identified by colony screening with
restriction enzyme digest (EcoR1, Promega) and agarose
electrophoresis, prior to liquid culture growth and plasmid prep
using the standard protocol of the Qiagen Qiaprep Spin Mini
Kit. In total, 233 clones (see Table 2 for details on a per monkey
basis) were sequenced using the M13 forward site on pCR2.1
using Big-Dye terminator chemistry on the Applied Biosystems
3100 Genetic Analyzer, by the DNA Sequencing Facility of
Florida State University, Department of Biological Sciences.
Sequences in this report are available from GenBank with
accession numbers DQ007650–DQ007882.
Sequence analysis and statistics
All sequence files were decoded using BioEdit version
6.0.7 (Hall, 1999). Sequences were roughly aligned using aFAST ClustalW algorithm (runs within BioEdit) and then
truncated to the 300 bases that encode the 99 amino acid first
exon. Then, sequences were grouped by individual animal for
a rigorous alignment using ClustalX with the IUB DNA
weight matrix and a transition to transversion ratio of 1.4
(Thompson et al., 1997). Aligned sequences were used to
calculate all pairwise DNA distances (BioEdit) or to generate
phylogenetic trees using a neighbor-joining method (Clus-
talX) (Saitou and Nei, 1987). All phylogenetic analyses used
the inoculum 17E sequence as a root. This virus was
sequenced at the start of the study and found to have two
nucleotide changes from the original GenBank deposition for
SIV/17E-Fr. The first change alters codon 44 from tyrosine to
serine, while the second change is silent. The frequencies of
synonymous mutations per synonymous site (dS) and nonsy-
nonymous mutations per nonsynonymous site (dN) were
estimated using the Synonymous/Nonsynonymous Analysis
Program (SNAP) from the Los Alamos National Labs (http://
hiv-web.lanl.gov/content/hiv-db/SNAP/WEBSNAP/SNAP.
html). Identical analyses were done to compare each time point
within individual monkeys, as in Fig. 2. Statistical comparison
of the average total pairwise distances of the monkeys in
Group A vs. B, A vs. C, and B vs. C was done using a one-
tailed t test (Table 2). To determine significance of changes in
pairwise distances or changes in dS and dN over time within
individual animals, the Wilcoxon signed rank test was
performed. The statistical cut-off for significance in these
analyses was P = 0.05.
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